Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA defends FDA's OTC office as "important focal point" for OTC policy issues.

This article was originally published in The Tan Sheet

Executive Summary

PhRMA CALLS OFFICE OF OTC DRUGS "IMPORTANT FOCAL POINT" FOR POLICY ISSUES involving nonprescription drugs in a section- by-section analysis of its draft FDA reform legislation that is being circulated on Capitol Hill. The Pharmaceutical Research & Manufacturers Association noted that, since its inception in the early 1990s, the Office of OTC Drug Evaluation "has gradually become an important focal point for policy issues" related to over-the-counter drugs, and "has played a constructive role in the consideration of each proposed switch of a drug from prescription to nonprescription status."
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel